- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02512185
Towards Optimal Prescription of Chemotherapy in Prostate Cancer (TOPCOP)
TOward Personalizing Care for Older Men With mCRPC - Understanding and Predicting Treatment Toxicities (the TOPCOP Study)
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Our primary aims are (a) to examine the impact of pre-treatment frailty on 'elder-relevant' outcomes including daily function, objective physical function, falls, quality of life (QOL), and early treatment discontinuation; (b) to determine whether the Hurria/Cancer and Aging Research Group (CARG) tool is able to predict severe (grade 3+) chemotherapy toxicity in men starting chemotherapy. Our secondary aim is to understand the impact of abiraterone and enzalutamide on 'elder-relevant' outcomes.
This is a prospective multicentre observational study. The investigators will enroll men age 65 or older with mCRPC who are starting (a) first-line chemotherapy; (b) abiraterone; or (c) enzalutamide. Assessments will occur prior to starting treatment and every 2 months thereafter until the end of treatment.
As treatment options become more complex in older men with mCRPC, understanding and predicting a wide range of treatment toxicities is important and will aid decision-making and management.
Studietype
Registrering (Faktiske)
Kontakter og plasseringer
Studiesteder
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Juravinski Cancer Centre
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre -KGH
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre
-
Toronto, Ontario, Canada, M4N 3M5
- Odette Cancer Centre
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- At least 65 years of age
- Diagnosed with prostate cancer with evidence of clinical and/or radiographic evidence of progression despite adequate androgen deprivation therapy and achievement of castration (total testosterone level <1.7 nmol/L measured within 6 months of enrollment)
- Among men starting either abiraterone or enzalutamide, no prior chemotherapy/abiraterone/enzalutamide. Among men starting first-line chemotherapy, commencing docetaxel but can have had either prior abiraterone or enzalutamide
Exclusion Criteria:
- Unable to speak English fluently.
- Severe neuropsychiatric abnormalities that prevent study participation.
- Limited life expectancy (<3 months) as estimated by the primary oncologist.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Chemotherapy
Men starting first-line chemotherapy for mCRPC (typically Docetaxel and Prednisone)
|
Abiraterone
Men with mCRPC starting Abiraterone
|
Enzalutamide
Men with mCRPC starting Enzalutamide
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Daily function assessed by questionnaires
Tidsramme: Participants will be followed for the duration of treatment up to 2 years
|
Daily function
|
Participants will be followed for the duration of treatment up to 2 years
|
Objective physical function
Tidsramme: Participants will be followed for the duration of treatment up to 2 years
|
Will be assessed by 3 physical performance measures
|
Participants will be followed for the duration of treatment up to 2 years
|
Grade 3+ toxicity using Common Terminology Criteria for Adverse Events (CTC-AE) version 4.0
Tidsramme: Participants will be followed for the duration of treatment up to 2 years
|
Toxicity
|
Participants will be followed for the duration of treatment up to 2 years
|
Number of falls provided by the participant
Tidsramme: Participants will be followed for the duration of treatment up to 2 years
|
Falls
|
Participants will be followed for the duration of treatment up to 2 years
|
Body fat percentage will be measured using a Tanita 300A analyzer
Tidsramme: Participants will be followed for the duration of treatment up to 2 years
|
Body composition analysis
|
Participants will be followed for the duration of treatment up to 2 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Quality of Life (QOL)
Tidsramme: Participants will be followed for the duration of treatment up to 2 years
|
FACT-G and FACT-P (specific for prostate cancer) questionnaires will be administered
|
Participants will be followed for the duration of treatment up to 2 years
|
The Montreal Cognitive Assessment (MoCA test) and Trail making tests A&B
Tidsramme: Participants will be followed for the duration of treatment up to 2 years
|
Cognition composite
|
Participants will be followed for the duration of treatment up to 2 years
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 15-9075
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .